01 — At a Glance
A Syringe Full of Surprises
- 52-Week High / Low₹2,131 / ₹1,200
- Q3 FY26 Revenue (₹ Mn)₹16,954 Mn
- Q3 FY26 PAT (₹ Mn)₹2,614 Mn
- Q3 FY26 EPS₹15.87
- Annualised EPS (Avg Q1–Q3 × 4)₹53.47
- Book Value₹580
- Price to Book2.92x
- Promoter (Fosun Pharma)51.83%
- Debt / Equity0.03x
- 3-Month Return-2.47%
Flash Summary: Gland Pharma posted Q3 FY26 consolidated revenue of ₹16,954 Mn (+22% YoY), adjusted EBITDA of ₹4,490 Mn at a 26% margin, and the long-suffering Cenexi subsidiary finally turned EBITDA-positive (EUR 1.4 Mn). The stock is up 8.36% in one year, down 2.47% in 3 months — and the CEO just announced his resignation effective April 30, 2026. Oh, and they’re expanding GLP-1 cartridge capacity 3.5x. All while trading at a P/E of 32.3x on an 11.9% ROCE. There is a lot to unpack here. Let’s crack the vial open.
02 — Introduction
The Injectable Empire Nobody Talks About at Dinner
Let’s be honest — “injectable pharmaceutical company” is not what you’d lead with at a party. You’d mention the Nifty IT darling or the EV startup. But Gland Pharma has been quietly jabbing its way to global relevance since 1978, shipping complex injectables to 60 countries, and holding over 1,736 product registrations worldwide. Your hospital’s IV bag might very well have started its life in Hyderabad. You’re welcome.
The company operates primarily B2B — they manufacture and supply to large pharma firms, hospitals, and institutional buyers, rather than chasing doctors with branded sales reps in expensive cars. 98% of revenue is B2B. It’s the pharmaceutical equivalent of being the airport that all airlines depend on, without getting any of the airline glory.
The story in Q3 FY26 is a genuine comeback narrative: revenue growing 22% YoY, the long-bleeding European subsidiary Cenexi finally reaching EBITDA positivity, 9 new US molecule launches in a single quarter, and a GLP-1 cartridge line expansion that management is being very conservative about — suspiciously conservative, some might say. The 9M FY26 revenue is ₹46,879 Mn (+12% YoY), and the adjusted EBITDA margin has improved to 25% from 22%.
Is this a turnaround? A re-rating story? Or just a company finally recovering from the hangover of a ₹1,000+ crore European acquisition made at the worst possible time? The injectable is being administered. Whether it cures or merely suppresses symptoms — read on.
Concall Note (Feb 2026): “Highest quarterly revenue during CY2025” — Cenexi CEO, referring to Q3. The same quarter the CEO of the parent company submitted his resignation. In pharma, things move fast. Sometimes in opposing directions simultaneously.
03 — Business Model: WTF Do They Even Do?
They Poke Things Into Other Things. Very Precisely.
Gland Pharma manufactures injectable pharmaceuticals — things that go into your bloodstream via a needle, not your digestive tract via a tablet. Think vials, ampoules, pre-filled syringes, lyophilized (fancy word for freeze-dried) powders, oncology drugs, and ophthalmic solutions. Across 15+ therapeutic areas. 89+ product SKUs. All made to the kind of sterility standards that make a surgery theatre look like a picnic blanket.
The business model is beautifully boring in its architecture: develop a complex injectable, get it approved by the US FDA (363 ANDAs filed, 304 approved), manufacture it at scale in Hyderabad, ship it to pharma giants in the US, Europe, Canada, and Australia who stick their own labels on it and sell it to hospitals. Gland doesn’t need a sales army — they need regulators to nod and clients to order. B2B at its purest.
In November 2022, they spent €120 Mn to acquire Cenexi — four European manufacturing sites across France and Belgium — to access the EU supply chain, controlled substances capability, and proximity to European tender processes. This acquisition bled EBITDA for two straight years. In Q3 FY26, Cenexi finally printed positive EBITDA. The street celebrated. Management immediately pointed to “quarterly fluctuations.” Classic pharmaceutical under-promise culture.
US Revenue Mix~49%Largest Geography
Europe Mix~18%via Cenexi
RoW Mix~20%Stable contributor
India Mix~5%B2C Direct
New frontier alert: GLP-1 injectable cartridges (think Ozempic-style pens). Gland is expanding cartridge fill-finish capacity from 40 Mn to 140 Mn units — the new line was being delivered as of the Feb 2026 concall. They’ve contracted 2–3 GLP-1 players already and have a pipeline of 6–7 more. Management is being so conservative about revenue assumptions that it’s actually suspicious. Either extreme caution or extreme strategy. We’ll know by FY28.
💬 Drop a comment: When you’re getting an IV drip at a hospital, does it comfort you or unsettle you to know it was likely manufactured by a B2B company you’ve never heard of?
04 — Financials Overview
Q3 FY26: The Numbers (in ₹ Millions, as reported)
Continue reading with a premium membership.
